Παρασκευή 12 Μαΐου 2017

Promising results for durvalumab against NSCLC, PFS endpoint met early. Recent atezo news may err on caution though… https://t.co/Izj8xaOqs5

Promising results for durvalumab against NSCLC, PFS endpoint met early. Recent atezo news may err on caution though… https://t.co/Izj8xaOqs5

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/863012081314004992
via IFTTT

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Δημοφιλείς αναρτήσεις